Complement iC3b Antibody (9)
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-11285
Key Product Details
Species Reactivity
Human
Applications
Immunoassay, Immunoprecipitation
Label
Unconjugated
Antibody Source
Monoclonal Rat IgG1 Clone # 9
Concentration
0.1 mg/ml
Product Specifications
Immunogen
The monocolonal antibody 9 (also known as YB2/90-5-20) reacts with a neoantigen on iC3, iC3b, C3dg and C3g.
Specificity
The monoclonal antibody 9 recognizes iC3b, C3dg and C3g in plasma. The monoclonal antibody does not recognize C3 or C3b.
Clonality
Monoclonal
Host
Rat
Isotype
IgG1
Description
Novus Biologicals Rat Complement iC3b Antibody (9) (NBP3-11285) is a monoclonal antibody validated for use in IP. All Novus Biologicals antibodies are covered by our 100% guarantee.
Applications for Complement iC3b Antibody (9)
Application
Recommended Usage
Immunoassay
Optimal dilutions of this antibody should be experimentally determined.
Immunoprecipitation
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50.
Formulation, Preparation, and Storage
Purification
Protein G purified
Formulation
0.2 um filtered solution in PBS, 0.1% BSA
Preservative
0.02% Sodium Azide
Concentration
0.1 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C.
Background: Complement iC3b
Alternate Names
Complement C3dg fragment, Complement C3g fragment, Complement fragment iC3b, iC3b, Inactivated C3b
Gene Symbol
C3
Additional Complement iC3b Products
Product Documents for Complement iC3b Antibody (9)
Product Specific Notices for Complement iC3b Antibody (9)
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...